12:00 AM
 | 
Jul 06, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cobiprostone: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in 124 osteoarthritis and/or rheumatoid arthritis patients taking 500 mg naproxen twice daily showed that oral cobiprostone did not significantly reduce the overall incidence of gastric ulcers vs. placebo at 12 weeks, the study's primary endpoint. The study evaluated 18...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >